Growth hormone is an essential element in the growth and development of the human body. It is its recombinant version that is the active ingredient in Pharmatropin 10 IU Pharmacom Labs. It is used for a variety of purposes, not only in the field of sport, but also in medicine. This medicine is available as an injectable solution. This makes it as bioavailable as possible, which guarantees fast action.
Benefits of Pharmatropin 10 IU Pharmacom Labs
Growth hormone is secreted by each person independently, but with age its concentration decreases. Moreover, its amount is not always the same. Growth hormone increases after exercise or other stress. Taking the drug also has the following effects:
- increase in muscle mass;
- slowing down the process of muscle destruction;
- reduction of body fat;
- acceleration of tissue regeneration;
- improved skin condition (rejuvenation);
- strengthening of bone tissue.
Somatotropin (growth hormone) is also known to increase immunity and stimulate bone growth. Most of the effects are due to the fact that when the level of somatotropin increases, an insulin-like growth factor is released. This is very important in sport.
Another important property of growth hormone is fat burning. The drug helps to lose weight, eliminates subcutaneous fat, which makes the relief more expressive. New muscle mass gained by taking somatotropin is dry and stiff.
The hormone is suitable for athletes who have suffered ligament or joint injuries or suffer from pain. It strengthens cartilage and accelerates tissue repair after damage.
Pharmatropin 10 IU Pharmacom Labs does not increase strength or endurance! It is not used in sports where these indicators are needed. For example, in powerlifting. It is necessary, in the first place, where the goal is to gain muscle mass and form a beautiful figure.
Possible negative effects
The drug is safe, as side effects are very rare and only when large doses are used. Possible problems:
- tunnel syndrome (compression of the nerve by surrounding tissue);
- hyperglycaemia (increased blood sugar);
- inhibition of the thyroid gland;
- increased pressure, swelling.
Most of the time, the hormone is taken without side effects. It does not affect libido and sexual function like many steroids with similar properties. After completing the course of somatotropin, there is no need for post-cycle therapy. It also does not cause gynecomastia or other diseases associated with excess estrogen, as it does not affect the work of sex hormones in any way.
Directions for taking the drug
The drug can be taken for 6 weeks or more. It is administered by injection. The dosage and frequency of application must be determined individually, depending on the physiological parameters of the person and their goals. As a general rule, the drug should be administered immediately before training or in the evening, i.e. at times when the natural hormone also increases.
In order to take somatotropin, you must exclude contraindications. To do this, consult your doctor. The drug is prohibited in the presence of neoplasms, as well as during pregnancy and breast-feeding. Only athletes who have already passed puberty (on average, after the age of 21 years) can take it. The drug is permitted for women.
List of references
- Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr. 2016;86(6):361-397.
- Colao A, Di Somma C, Pivonello R, et al. Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer. 2008;15(4):905-915.
- Growth Hormone (GH) Replacement Therapy in Adults with GH Deficiency. J Clin Endocrinol Metab. 1998;83(2):383-384.
- Loche S, Salerno M, Garofalo P, et al. Growth Hormone (GH) Deficiency in Childhood: Updates and Guidelines. J Clin Res Pediatr Endocrinol. 2016;8(Suppl 1):1-8.
- Jørgensen JO, Juul A, Kastrup KW, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1989;1(8649):1221-1225.